Research Roundup

OFFICIAL PUBLICATION OF

by its subsidiary APPco

Debbie Rigby 24/10/2017

Debbie Rigby takes a look at the latest in research news Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations Onabotulinum toxin A (BoNT-A) is approved treatment for the prevention of chronic migraine. Its efficacy increases considerably over time during long-term treatments, significantly varying among patients. Short duration of migraine,

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘Consumer confusion, pharmacist frustration’ if current system continues

I welcome Mark's move, at least someone talks about it. But like any push at the forefront, it comes with…

Benjamyn Sung

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

Research Roundup

Previous Government tactics under fire

Next Vaping nicotine linked to later smoking

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Government tactics under fire

Next Vaping nicotine linked to later smoking

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.